ATC Group: J07BK Varicella zoster vaccines

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J07BK in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J07 Vaccines
3 J07B Viral vaccines
4 J07BK Varicella zoster vaccines

Group J07BK contents

Code Title
J07BK01 Varicella, live attenuated
J07BK02 Zoster, live attenuated
J07BK03

Active ingredients in J07BK

Active Ingredient Description
Varicella, live attenuated

Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity.

Attenuated varicella-zoster virus

Varicella-zoster virus vaccine was shown to boost VZV-specific immunity, which is thought to be the mechanism by which it protects against zoster and its complications.

Related product monographs

Title Information Source Document Type  
SHINGRIX Powder for suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
VARILRIX Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZOSTAVAX Powder and solvent for suspension for injection European Medicines Agency (EU) MPI, EU: SmPC